GEORGETOWN, Texas--(BUSINESS WIRE)--Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapies, announced today that the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) Application to initiate clinical studies for MT-3724 as monotherapy for the treatment of refractory non-Hodgkin’s lymphoma (NHL). MT-3724 is the Company’s lead next-generation immunotoxin compound. MT-3724 is capable of forcing internalization against the CD20 B-cell surface marker and inducing direct cell death via ribosome inactivation in CD20-expressing cells. MT-3724 is the first successful immunotoxin to CD20 and represents a novel mechanism of action in the treatment of NHL.
Help employers find you! Check out all the jobs and post your resume.
